Document Detail


Ongoing NovoSeven trials.
MedLine Citation:
PMID:  12404094     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Recombinant activated factor VII (rFVIIa, 'NovoSeven' was initially developed for the treatment of bleeding in patients with haemophilia and inhibitors, and is currently licensed in most countries worldwide. The mechanism of action suggests that its enhancing effects in haemostasis are limited to the site of injury and that systemic activation of the coagulation cascade does not occur. These properties, together with anecdotal reports of its beneficial effects in different patient populations with severe bleeds, suggest that rFVIIa may be valuable as a general haemostatic agent. In case reports, rFVIIa has been reported to reduce bleeding in patients with liver disease, thrombocytopenia or thrombocytopathia, trauma those undergoing radical prostatectomy or receiving oral anticoagulant therapy. A number of clinical trials have recently been initiated to collect data on the safety and efficacy of rFVIIa in these patient groups. The beneficial effects of rFVIIa occurring in these studies will support the potential use of rFVIIa as a universal haemostatic agent.
Authors:
Elisabeth Erhardtsen
Related Documents :
12897104 - Effects of argatroban as an anticoagulant for haemodialysis in patients with antithromb...
17534704 - High macrophage migration inhibitory factor levels in disseminated intravascular coagul...
1826974 - Measurements of tissue factor-like activity in plasma of patients with dic.
16969634 - Decreased protein s activity is related to the disease activity of behcet's disease.
10520414 - Idiopathic growth hormone deficiency: presentation, diagnostic and treatment during chi...
3706684 - An investigation of factors affecting postoperative rewarming of adult patients.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Intensive care medicine     Volume:  28 Suppl 2     ISSN:  0342-4642     ISO Abbreviation:  Intensive Care Med     Publication Date:  2002 Oct 
Date Detail:
Created Date:  2002-10-29     Completed Date:  2003-05-23     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  7704851     Medline TA:  Intensive Care Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  S248-55     Citation Subset:  IM    
Affiliation:
Novo Nordisk, Krogshosvej 53A, 2880 Bagsvaerd, Denmark. eer@novonordisk.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Blood Coagulation Disorders / drug therapy*
Blood Loss, Surgical / prevention & control
Clinical Trials as Topic*
Factor VII / therapeutic use*
Factor VIIa
Hemorrhage / drug therapy
Humans
Recombinant Proteins / therapeutic use*
Chemical
Reg. No./Substance:
0/Recombinant Proteins; 0/recombinant FVIIa; 9001-25-6/Factor VII; EC 3.4.21.21/Factor VIIa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Updates in the management of severe coagulopathy in trauma patients.
Next Document:  Marfan syndrome in the third Millennium.